ArticleJournal of medical ultrasonics (2001)2026
Dynamic contrast-enhanced ultrasound with quantitative analysis optimizes LI-RADS for hepatocellular carcinoma diagnosis: a multicenter study.
Article in Journal of medical ultrasonics (2001), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo investigate the value of dynamic contrast-enhanced ultrasound (DCE-US) analysis using the Liver Imaging Reporting and Data System (LI-RADS) to improve the diagnosis of hepatocellular carcinoma (HCC).
methodsThis multicenter study retrospectively enrolled consecutive high-risk patients for HCC who underwent contrast-enhanced ultrasound (CEUS) between December 2022 and June 2023. Quantitative CEUS analysis was performed using VueBox
results269 patients (median age, 61 years [interquartile range, 52-69]; 206 men, 63 women) with 269 focal liver lesions (FLLs) (median size, 40 mm [interquartile range, 25-62 mm]) were included. Among the 269 FLLs, 227 were HCC, 31 non-HCC malignancies, and 11 benign lesions. DCE-US analysis showed HCC had higher rise time (RT) and fall time (FT) at the lesion margin than non-HCC malignancies (both P < 0.05) but lower RT and FT than benign lesions (both P < 0.05). RT at the lesion margin (range 17.48 s-21.16 s) serves as an auxiliary indicator for HCC diagnosis. Compared to CEUS LI-RADS, the revised LR-5 improved sensitivity (61.7 vs. 52.8%, P < 0.001) without a significant decrease in specificity (76.2 vs. 83.3%, P = 0.25) for diagnosing HCC.
conclusionDCE-US quantitative analysis improved the sensitivity for HCC diagnosis without affecting specificity, thereby optimizing the diagnostic performance of CEUS LI-RADS.
Indexed as
Identifiers
40999259What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.